Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. (ORMP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ORMP · as of Sep 30, 2025
Ownership Breakdown
47
Institutional Holders
▼ 2 vs Q2
$24.31M
Total Inst. Value
▲ $8.00M vs Q2
40.93M
Shares Outstanding
freeFloat 77.25%
9.21M
13F Shares Held
▲ 1.96M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ORMP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BML CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.17M | 7.59% | 7.59% | $8.36B | Nov 10, 2025 | ▲ 84.0K |
pharmaceutical preparations | 1.97M | 4.73% | 4.73% | $5.21B | Jan 12, 2026 | NEW |
MURCHINSON LTD. pharmaceutical preparations | 1.75M | 4.20% | 4.20% | $4.62B | Nov 14, 2025 | — held |
BOOTHBAY FUND MANAGEMENT, LLC pharmaceutical preparations | 845.4K | 2.03% | 2.03% | $2.23B | Nov 14, 2025 | — held |
RATHBONES GROUP PLC pharmaceutical preparations | 233.0K | 55.82% | 55.82% | $615.17M | Nov 13, 2025 | — held |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 149.7K | 35.85% | 35.85% | $395.12M | Feb 3, 2026 | ▲ 6.3K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 148.9K | 35.67% | 35.67% | $393.10M | Nov 13, 2025 | ▲ 4.7K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 147.5K | 35.33% | 35.33% | $389.37M | Nov 12, 2025 | ▼ 19.4K |
WELLS FARGO & COMPANY/MN pharmaceutical preparations | 130.1K | 31.16% | 31.16% | $343.43M | Nov 13, 2025 | ▲ 109.1K |
CITADEL ADVISORS LLC pharmaceutical preparations | 111.7K | 26.76% | 26.76% | $294.91M | Nov 14, 2025 | ▲ 24.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
9
Increased
+271.0K shares5
New Positions
first time holders10
Decreased
−152.9K shares3
Sold Out
fully exitedNet shares change (top 50)
+118.1K
+271.0K / −152.9K
Net new holders
+1
5 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ORMP insider trading · insider activity
Source: SEC Form 4
8
Buy transactions
8
Sell transactions
1.00
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
KIDRON NADAV President and CEO | Mar 30, 2026 | Tax Withhold | 44,818 | $3.31 | $148.3K | 3.42M | Form 4 ↗ |
Kidron Miriam Chief Scientific Officer | Mar 30, 2026 | Tax Withhold | 435,084 | $3.31 | $1.44M | 1.13M | Form 4 ↗ |
Kidron Miriam Chief Scientific Officer | Mar 17, 2026 | Award | 119,558 | — | — | 1.57M | Form 4 ↗ |
KIDRON NADAV President and CEO | Mar 17, 2026 | Award | 167,005 | — | — | 3.42M | Form 4 ↗ |
Hexter Joshua COO & CBO | Mar 17, 2026 | Award | 95,889 | — | — | 1.16M | Form 4 ↗ |
Gabay Avraham Chief Financial Officer | Mar 17, 2026 | Award | 95,889 | — | — | 745.1K | Form 4 ↗ |
KIDRON NADAV President and CEO | Mar 12, 2026 | Gift | 100,000 | — | — | 3.26M | Form 4 ↗ |
Kidron Miriam Chief Scientific Officer | Jan 14, 2026 | Gift | 86,166 | — | — | 1.34M | Form 4 ↗ |
Reznick Yehuda director | Dec 31, 2025 | Award | 6,250 | — | — | 105.2K | Form 4 ↗ |
Reznick Yehuda director | Dec 31, 2025 | Award | 30,000 | $0.01 | $360 | 98.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Oramed Pharmaceuticals Inc. (ORMP) is primarily owned by institutional investors, who hold approximately 22.5% of total shares outstanding. Company insiders own approximately 22.75%, while retail and public investors account for the remaining 54.74%.
The largest institutional shareholder of Oramed Pharmaceuticals Inc. is BML CAPITAL MANAGEMENT, LLC, holding approximately 3.17 million shares — equal to 7.59% of outstanding shares — as of September 30, 2025.
A total of 47 institutional investors currently hold ORMP stock, with a combined institutional value of approximately $24,309,179 as of the most recent 13F filing period.
Frequently asked questions
ORMP ownershipOramed Pharmaceuticals Inc. (ORMP) is primarily owned by institutional investors, who hold approximately 22.5% of shares. The largest shareholder is BML CAPITAL MANAGEMENT, LLC with a 7.59% stake. Company insiders hold 22.75%. Data sourced from SEC Form 13F as of September 30, 2025.